Vaxart, Inc., a privately held, clinical-stage company developing vaccines that are administered by tablet rather than by injection, today announced that Vaxart CEO Wouter Latour, MD, will present a corporate overview at the 7th Annual Biotech Showcase on Wednesday, January 14, 2015 at 8:15 a.m. PST. The event will be held at the Parc 55 Wyndham Hotel in San Francisco. Dr. Latour and Vaxart CFO John Harland will also be available to participate in one-on-one meetings with registered attendees.
About Vaxart
Vaxart is a privately held company developing oral recombinant vaccines based on its proprietary delivery platform. The Vaxart platform is suitable for delivering any protein antigen such as those used in currently marketed influenza, hepatitis B and human papilloma virus (HPV) vaccines. By eliminating needles, Vaxart’s temperature-stable tablet vaccines offer a wide range of advantages such as: convenience, acceptance, self-administration, reduced cold chain requirements, reduced medical waste, and rapid and scalable manufacturing. For more information, please visit www.vaxart.com.
